GZR101 vs Insulin sudelidec (INS068)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: Insulin receptor (basal) · full Type 2 Diabetes pipeline

GZR101

Developed by Gan & Lee Pharmaceuticals

Phase 2 in Type 2 Diabetespeptide
Partial signal

NCT06199505 · Phase 2 · completed

The study used randomization and an active comparator, but it was open-label and had a surrogate primary endpoint—change in HbA1c rather than a hard clinical outcome. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: February 2027 · NCT07387003 (registry estimate)

Reported efficacy

Change in HbA1c (Baseline to week 16): Change in HbA1c from baseline to week 16: Part A GZR101 once-daily -1.56% vs IDegAsp once-daily -1.31% (difference -0.24%); Part B GZR101+aspart once-daily -1.64% and twice-daily -1.68% vs IDegAsp twice-daily -1.59% (differences -0.06% and -0.09%). (met)

Result source: NCT06199505

Insulin sudelidec (INS068)

Marketed by Jiangsu Hengrui Pharmaceuticals

Phase 3 in Type 2 Diabetespeptide
Partial signal

NCT05699408 · Phase 3 · completed

This Phase 3 trial randomly assigned 513 people with type 2 diabetes to insulin sudelidec or to insulin glargine, alongside their existing oral diabetes medicines. It was open-label, so treatment assignment was known throughout. HbA1c fell by 1.34 percentage points on insulin sudelidec against 1.37 on insulin glargine, a difference of 0.02 points (95% CI -0.14 to 0.18), meeting the prespecified test that it was not worse than glargine.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Reported efficacy

Change in HbA1c (Week 0 to Week 26): Change in HbA1c at Week 26 (Study 302, oral-antidiabetic-drug background, n=513): insulin sudelidec (INS068) -1.34% vs insulin glargine -1.37%; between-group difference 0.02% (95% CI -0.14% to 0.18%) (met)

Result source: NCT05699408

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointGZR101Insulin sudelidec (INS068)
HbA1c, change-1.6% vs -1.3%avs IDegAsp once-dailywk 16NCT06199505
2 other results
-1.3% vs -1.4%avs insulin glarginewk 26NCT05699408
Body weight, change (kg)—Not reported—Not posted · NCT05699408
HbA1c below 7%—Not reported—Not posted · NCT05699408
Fasting plasma glucose, change—Not reported—Not posted · NCT05699408
3-point MACE (% with event)—Not reported—Not posted · NCT05699408

HbA1c, change

GZR101
-1.6% vs -1.3%avs IDegAsp once-dailywk 16NCT06199505
2 other results
Insulin sudelidec (INS068)
-1.3% vs -1.4%avs insulin glarginewk 26NCT05699408

Body weight, change (kg)

GZR101
—Not reported
Insulin sudelidec (INS068)
—Not posted · NCT05699408

HbA1c below 7%

GZR101
—Not reported
Insulin sudelidec (INS068)
—Not posted · NCT05699408

Fasting plasma glucose, change

GZR101
—Not reported
Insulin sudelidec (INS068)
—Not posted · NCT05699408

3-point MACE (% with event)

GZR101
—Not reported
Insulin sudelidec (INS068)
—Not posted · NCT05699408
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: GZR101's landscape · Insulin sudelidec (INS068)'s landscape